Workflow
永顺生物(839729) - 2022 Q1 - 季度财报
WINSUN BIOWINSUN BIO(BJ:839729)2022-04-21 16:00

Financial Performance - Net profit attributable to shareholders for Q1 2022 was CNY 17,329,287.65, a decrease of 46.62% compared to CNY 32,464,384.86 in Q1 2021[18] - Operating revenue for Q1 2022 was CNY 78,677,625.48, down 25.46% from CNY 105,555,621.75 in the same period last year[18] - The company's cash flow from operating activities for Q1 2022 was CNY 156,921.63, a significant decline of 98.54% compared to CNY 10,747,970.03 in Q1 2021[18] - Operating revenue decreased by 25.46% year-on-year, resulting in an operating profit of 19,840,341.00, down 45.55%[22] - Net profit fell to 17,329,287.65, a decline of 46.62% compared to the previous year[22] - Net cash flow from operating activities dropped by 98.54%, amounting to 156,921.63, primarily due to a decrease in sales revenue[23] - The company reported a financial income of CNY 1,195,712.31 in Q1 2022, down from CNY 3,182,549.43 in Q1 2021, a decline of 62.5%[63] - The net profit for the first quarter of 2022 was CNY 17,322,251, a decrease of 46.5% compared to CNY 32,463,364 in the same period of 2021[68] - The operating profit for the first quarter of 2022 was CNY 19,833,124, down 45.5% from CNY 36,433,363 in the first quarter of 2021[68] - The total comprehensive income for the first quarter of 2022 was CNY 17,322,251, a decrease of 46.5% from CNY 32,463,365 in the first quarter of 2021[68] Assets and Liabilities - Total assets as of March 31, 2022, amounted to CNY 816,909,425.89, reflecting a 0.96% increase from CNY 809,181,608.59 at the end of the previous year[18] - The company's total liabilities to assets ratio was 11.53% as of March 31, 2022, down from 12.83% at the end of the previous year[18] - The total liabilities decreased to CNY 94,196,583.67 from CNY 103,796,628.70 during the same period[56] - The company's total equity increased to CNY 722,712,842.22 as of March 31, 2022, compared to CNY 705,384,979.89 at the end of 2021[56] - The total current assets as of March 31, 2022, amounted to CNY 558,995,324.61, an increase from CNY 547,385,566.32 as of December 31, 2021[54] - The company's fixed assets as of March 31, 2022, were valued at CNY 224,186,004.07, a slight decrease from CNY 230,352,331.89 at the end of 2021[55] Cash Flow - Net cash flow from investing activities was -7,969,673.22, a decrease of 121.24%, mainly due to the redemption of bank wealth management products in the previous year[23] - The investment activities generated a net cash flow of CNY -7,969,673 in the first quarter of 2022, compared to CNY 37,513,662 in the same period of 2021[71] - Cash inflow from operating activities totaled ¥61,793,189.43, a decrease of 32% from ¥90,754,811.00[74] - Cash outflow from operating activities amounted to ¥61,643,415.40, down 23% from ¥80,007,890.35[74] - Net cash flow from operating activities was ¥149,774.03, significantly lower than ¥10,746,920.65 in the previous period[74] - The ending balance of cash and cash equivalents was ¥199,917,514.25, a decrease from ¥440,010,362.03[74] Shareholder Information - The total share capital remains at 273,350,000, with 39.06% held by Guangdong Province and 19.71% by Guangdong Agricultural Science and Technology Investment Co., Ltd.[29] - The company has a total of 4,149 common shareholders[29] - The proportion of unrestricted shares is 29.36%, while restricted shares account for 70.64% of the total[29] - The total shareholding of major shareholders is 221,549,857 shares, representing 81.05% of the total shares[34] Commitments and Compliance - The company has committed to strictly adhering to all promises made during the public offering process, with no violations reported during the period[50] - The company has committed to fulfilling the dilution compensation measures, which have been adhered to without violation during the reporting period[48] - The company assures that the undistributed profits prior to the public offering will be shared among new and old shareholders according to their shareholding ratios, and this commitment has been maintained without breach[49] - The company has commitments in place to avoid related party transactions, which have been fulfilled without any violations during the reporting period[40] - The major shareholders have made commitments to avoid competition and have complied with these commitments during the reporting period[43] Challenges and Future Outlook - The company is facing challenges due to the downturn in the aquaculture industry and the impact of the COVID-19 pandemic[22] - Future strategies and product developments were not detailed in the provided content[22] Legal and Internal Control - There were no significant legal disputes or financial guarantees reported during the period[35] - The company’s internal control systems have been continuously improved, with no significant failures reported[42]